Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease

키워드

참고문헌 (100)

1. Burger D, "Conventional medical management of inflammatory bowel disease", Gastroenterology, 140, pp.1827~1837 (2011)
2. Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
3. Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
4. Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderateto-severe ulcerative colitis", Gastroenterology, 142, pp.257~265 (2012)
5. Targan SR, "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease", N Engl J Med, 337, pp.1029~1035 (1997)
6. Hanauer SB, "Human anti-tumor necrosis factor monoclonal antibody(adalimumab)in Crohn’s disease : the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
7. Schreiber S, "Maintenance therapy with certolizumab pegol for Crohn’s disease", N Engl J Med, 357, pp.239~250 (2007)
8. Sokol H, "Complications and surgery in the inflammatory bowel diseases biological era", Curr Opin Gastroenterol, 30, pp.378~384 (2014)
9. Yarur AJ, "Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease", Aliment Pharmacol Ther, 45, pp.933~940 (2017)
10. Amiot A, "Long-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy : a cohort study from the GETAID", Am J Gastroenterol, 109, pp.1443~1449 (2014)
11. Sandborn WJ, "Adalimumab for maintenance treatment of Crohn’s disease : results of the CLASSIC II trial", Gut, 56, pp.1232~1239 (2007)
12. Hanauer SB, "Maintenance infliximab for Crohn’s disease : the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
13. Allez M, "Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects", J Crohns Colitis, 4, pp.355~366 (2010)
14. D’Haens GR, "The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?", Am J Gastroenterol, 106, pp.199~212 (2011)
15. Ben-Horin S, "Review article : loss of response to anti-TNF treatments in Crohn’s disease", Aliment Pharmacol Ther, 33, pp.987~995 (2011)
16. Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease", Gastroenterology, 134, pp.929~936 (2008)
17. Andersen NN, "Risk of infections associated with biological treatment in inflammatory bowel disease", World J Gastroenterol, 20, pp.16014~16019 (2014)
18. Siegel CA, "Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease : a meta-analysis", Clin Gastroenterol Hepatol, 7, pp.874~881 (2009)
19. Wan H, "An overall comparison of small molecules and large biologics in ADME testing", ADMET DMPK, 4, pp.1~22 (2016)
20. Chande N, "Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease", Cochrane Database Syst Rev, 2015(10), pp.CD000067~ (2015)
21. Timmer A, "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, 2016(5), pp.CD000478~ (2016)
22. Jovani M, "Vedolizumab for the treatment of IBD : a selective therapeutic approach targeting pathogenic a4b7 cells", Curr Drug Targets, 14, pp.1433~1443 (2013)
23. Lobatón T, "Review article : anti-adhesion therapies for inflammatory bowel disease", Aliment Pharmacol Ther, 39, pp.579~594 (2014)
24. Zundler S, "Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects", Front Immunol, 8, pp.891~ (2017)
25. Sandborn WJ, "Natalizumab induction and maintenance therapy for Crohn’s disease", N Engl J Med, 353, pp.1912~1925 (2005)
26. Targan SR, "Natalizumab for the treatment of active Crohn’s disease : results of the ENCORE Trial", Gastroenterology, 132, pp.1672~1683 (2007)
27. del Pilar Martin M, "Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab", Arch Neurol, 65, pp.1596~1603 (2008)
28. Kleinschmidt-DeMasters BK, "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis", N Engl J Med, 353, pp.369~374 (2005)
29. Langer-Gould A, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab", N Engl J Med, 353, pp.375~381 (2005)
30. Bloomgren G, "Risk of natalizumab-associated progressive multifocal leukoencephalopathy", N Engl J Med, 366, pp.1870~1880 (2012)
31. Gordon FH, "A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin", Aliment Pharmacol Ther, 16, pp.699~705 (2002)
32. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
33. Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn’s disease", N Engl J Med, 369, pp.711~721 (2013)
34. Sands BE, "Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed", Gastroenterology, 147, pp.618~627 (2014)
35. Feagan BG, "Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists", Clin Gastroenterol Hepatol, 15, pp.229~239 (2017)
36. Sands BE, "Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy", Inflamm Bowel Dis, 23, pp.97~106 (2017)
37. Loftus EV Jr, "Long-term efficacy of vedolizumab for ulcerative colitis", J Crohns Colitis, 11, pp.400~411 (2017)
38. Vermeire S, "Long-term efficacy of vedolizumab for Crohn’s disease", J Crohns Colitis, 11, pp.412~424 (2017)
39. Milch C, "Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype", J Neuroimmunol, 264, pp.123~126 (2013)
40. Colombel JF, "The safety of vedolizumab for ulcerative colitis and Crohn’s disease", Gut, 66, pp.839~851 (2017)
41. Benson JM, "Discovery and mechanism of ustekinumab : a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders", MAbs, 3, pp.535~545 (2011)
42. Fuss IJ, "Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody", Inflamm Bowel Dis, 12, pp.9~15 (2006)
43. Wittig BM, "Drug evaluation : CNTO-1275, a mAb against IL-12", IL-23p40 for the potential treatment of inflammatory diseases, 2007, pp.8, 947~954
44. Feagan BG, "Ustekinumab as induction and maintenance therapy for Crohn’s disease", N Engl J Med, 375, pp.1946~1960 (2016)
45. Toshifumi Hibi, "Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies", Intestinal research, 15(4), pp.475~486 (2017), 대한장연구학회
46. Sandborn WJ, "Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy", Aliment Pharmacol Ther, 48, pp.65~77 (2018)
47. Papp KA, "Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis : final results from 5 years of follow-up", Br J Dermatol, 168, pp.844~854 (2013)
48. Menter A, "Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis : results from the Psoriasis Longitudinal Assessment and Registry(PSOLAR)", J Eur Acad Dermatol Venereol, 30, pp.1148~1158 (2016)
49. Papp K, "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry(PSOLAR)", J Drugs Dermatol, 14, pp.706~714 (2015)
50. Shuai K, "Regulation of JAK-STAT signalling in the immune system", Nat Rev Immunol, 3, pp.900~911 (2003)
51. Murray PJ, "The JAK-STAT signaling pathway : input and output integration", J Immunol, 178, pp.2623~2629 (2007)
52. Ghoreschi K, "Janus kinases in immune cell signaling", Immunol Rev, 228, pp.273~287 (2009)
53. Olivera P, "Next generation of small molecules in inflammatory bowel disease", Gut, 66, pp.199~209 (2017)
54. Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 376, pp.1723~1736 (2017)
55. Sandborn WJ, "Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials", Clin Gastroenterol Hepatol, 17, pp.1541~1550 (2019)
56. Charles-Schoeman C, "Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor", Semin Arthritis Rheum, 46, pp.261~271 (2016)
57. Sandborn WJ, "A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease", Clin Gastroenterol Hepatol, 12, pp.1485~1493 (2014)
58. Panés J, "Tofacitinib for induction and maintenance therapy of Crohn’s disease : results of two phase IIb randomized placebo-controlled trials", Gut, 66, pp.1049~1059 (2017)
59. Tang MT, "Review article : nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease", Aliment Pharmacol Ther, 47, pp.1440~1452 (2018)
60. Cepek KL, "Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells", J Immunol, 150(8 Pt 1), pp.3459~3470 (1993)
61. Vermeire S, "Etrolizumab as induction therapy for ulcerative colitis : a randomised, controlled, phase 2trial", Lancet, 384, pp.309~318 (2014)
62. Selinger C, "OTU-003 Etrolizumab as induction therapy in moderate to severe Crohn’s disease: results from bergamot cohort 1", Gut, 67(Suppl 1), pp.A53~A53 (2018)
63. Vermeire S, "The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis : a randomised study", Gut, 60, pp.1068~1075 (2011)
64. Vermeire S, "Anti-MAdCAM antibody(PF-00547659)for ulcerative colitis(TURANDOT) : a phase 2, randomised, double-blind, placebo-controlled trial", Lancet, 390, pp.135~144 (2017)
65. Sandborn WJ, "Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease : report of the OPERA study", Gut, 67, pp.1824~1835 (2018)
66. Feagan BG, "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease : a randomised, double-blind, placebo-controlled phase 2 study", Lancet, 389, pp.1699~1709 (2017)
67. Feagan BG, "Risankizumab in patients with moderate to severe Crohn’s disease : an open-label extension study", Lancet Gastroenterol Hepatol, 3, pp.671~680 (2018)
68. Sands BE, "Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease : a phase 2a study", Gastroenterology, 153, pp.77~86 (2017)
69. Mannon PJ, "Anti-interleukin-12 antibody for active Crohn’s disease", N Engl J Med, 351, pp.2069~2079 (2004)
70. Panaccione R, "Briakinumab for treatment of Crohn’s disease : results of a randomized trial", Inflamm Bowel Dis, 21, pp.1329~1340 (2015)
71. Vermeire S, "Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib(the FITZROY study) : results from a phase 2, doubleblind, randomised, placebo-controlled trial", Lancet, 389, pp.266~275 (2017)
72. Sandborn WJ, "Safety and efficacy of ABT-494(upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn’s disease : results from Celest", Gastroenterology, 152, pp.S1308~ (2017)[DOI]
73. Marafini I, "TGFbeta signaling manipulation as potential therapy for IBD", Curr Drug Targets, 14, pp.1400~1404 (2013)
74. Monteleone G, "Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease", J Clin Invest, 108, pp.601~609 (2001)
75. Boirivant M, "Inhibition of Smad7with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis", Gastroenterology, 131, pp.1786~1798 (2006)
76. Monteleone G, "Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease", N Engl J Med, 372, pp.1104~1113 (2015)
77. Spadaccini M, "PDE4inhibition and inflammatory bowel disease: a novel therapeutic avenue", Int J Mol Sci, 18, pp.E1276~ (2017)
78. Danese S, "OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study", Crohns Colitis, 12(Suppl 1), pp.S004~ (2018)
79. Sanchez T, "Structural and functional characteristics of S1P receptors", J Cell Biochem, 92, pp.913~922 (2004)
80. Peyrin-Biroulet L, "Modulation of sphingosine-1-phosphate in inflammatory bowel disease", Autoimmun Rev, 16, pp.495~503 (2017)
81. Mullershausen F, "Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors", Nat Chem Biol, 5, pp.428~434 (2009)
82. O’Sullivan C, "The structure and function of the S1P1 receptor", Trends Pharmacol Sci, 34, pp.401~412 (2013)
83. Scott FL, "Ozanimod(RPC1063)is a potent sphingosine-1-phosphate receptor-1(S1P1)and receptor-5(S1P5)agonist with autoimmune disease-modifying activity", Br J Pharmacol, 173, pp.1778~1792 (2016)
84. Sandborn WJ, "Ozanimod induction and maintenance treatment for ulcerative colitis", N Engl J Med, 374, pp.1754~1762 (2016)
85. "Posters of distinction P-001 to P-018", Am J Gastroenterol, 113, pp.S1~S5 (2018)
86. "Inflammatory Bowel Disease (Abstracts 568-744)", The American Journal of Gastroenterology (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
87. Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease", N Engl J Med, 362, pp.1383~1395 (2010)
88. Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis", Gastroenterology, 146, pp.392~400 (2014)
89. Matsumoto T, "Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease : a prospective, randomized trial", J Crohns Colitis, 10, pp.1259~1266 (2016)
90. Sands BE, "Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab", Inflamm Bowel Dis, 13, pp.2~11 (2007)
91. Hirten RP, "Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders", Clin Gastroenterol Hepatol, 16, pp.1374~1384 (2018)
92. van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
93. Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
94. Bennet JD, "Treatment of ulcerative colitis by implantation of normal colonic flora", Lancet, 1, pp.164~ (1989)
95. Paramsothy S, "Faecal microbiota transplantation for inflammatory bowel disease : a systematic review and meta-analysis", J Crohns Colitis, 11, pp.1180~1199 (2017)
96. Narula N, "Systematic review and metaanalysis : fecal microbiota transplantation for treatment of active ulcerative colitis", Inflamm Bowel Dis, 23, pp.1702~1709 (2017)
97. 나수영, "염증성 장질환에서 치료 전략의 진화", 대한소화기학회지, 71(2), pp.61~68 (2018), 대한소화기학회[DOI]
98. Okamoto R, "Investigating cell therapy for inflammatory bowel disease", Expert Opin Biol Ther, 16, pp.1015~1023 (2016)
99. Hawkey CJ, "Autologous hematopoetic stem cell transplantation for refractory Crohn disease : a randomized clinical trial", JAMA, 314, pp.2524~2534 (2015)
100. Panés J, "Expanded allogeneic adipose-derived mesenchymal stem cells(Cx601)for complex perianal fistulas in Crohn’s disease : a phase 3 randomised, double-blind controlled trial", Lancet, 388, pp.1281~1290 (2016)

관련 논문AI추천